CYBB
NADPH oxidase 2
Also known as: CGD, CY24B_HUMAN, GP91-PHOX, NOX2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P04839
- Gene
- CYBB
- Ensembl
- ENSG00000165168
- Chromosome
- X
- Canonical length
- 570 aa
- Protein class
- Disease related genes, Human disease related genes, Potential drug targets, Predicted membrane proteins, Transporters
OverviewNCBI Gene
Cytochrome b (-245) is composed of cytochrome b alpha (CYBA) and beta (CYBB) chain. It has been proposed as a primary component of the microbicidal oxidase system of phagocytes. CYBB deficiency is one of five described biochemical defects associated with chronic granulomatous disease (CGD). In this disorder, there is decreased activity of phagocyte NADPH oxidase; neutrophils are able to phagocytize bacteria but cannot kill them in the phagocytic vacuoles. The cause of the killing defect is an inability to increase the cell's respiration and consequent failure to deliver activated oxygen into the phagocytic vacuole. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
570 residues, UniProt reviewed canonical sequence.
>P04839|CYBB
1 MGNWAVNEGL SIFVILVWLG LNVFLFVWYY RVYDIPPKFF YTRKLLGSAL ALARAPAACL
61 NFNCMLILLP VCRNLLSFLR GSSACCSTRV RRQLDRNLTF HKMVAWMIAL HSAIHTIAHL
121 FNVEWCVNAR VNNSDPYSVA LSELGDRQNE SYLNFARKRI KNPEGGLYLA VTLLAGITGV
181 VITLCLILII TSSTKTIRRS YFEVFWYTHH LFVIFFIGLA IHGAERIVRG QTAESLAVHN
241 ITVCEQKISE WGKIKECPIP QFAGNPPMTW KWIVGPMFLY LCERLVRFWR SQQKVVITKV
301 VTHPFKTIEL QMKKKGFKME VGQYIFVKCP KVSKLEWHPF TLTSAPEEDF FSIHIRIVGD
361 WTEGLFNACG CDKQEFQDAW KLPKIAVDGP FGTASEDVFS YEVVMLVGAG IGVTPFASIL
421 KSVWYKYCNN ATNLKLKKIY FYWLCRDTHA FEWFADLLQL LESQMQERNN AGFLSYNIYL
481 TGWDESQANH FAVHHDEEKD VITGLKQKTL YGRPNWDNEF KTIASQHPNT RIGVFLCGPE
541 ALAETLSKQS ISNSESGPRG VHFIFNKENFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CYBB can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 6
- Mean surface accessibility (rSASA)
- 0.26
- Highest tissue expression
- 150 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 150 nTPM
- appendix: 141 nTPM
- lymph node: 86 nTPM
- lung: 84 nTPM
- spleen: 79 nTPM
- tonsil: 65 nTPM
Single-cell type
- neutrophil progenitors: 1,958 nCPM
- monocytes: 776 nCPM
- kupffer cells: 613 nCPM
- macrophages: 418 nCPM
- microglia: 358 nCPM
- neutrophils: 352 nCPM
Immune cell
- classical monocyte: 319 nTPM
- intermediate monocyte: 241 nTPM
- non-classical monocyte: 227 nTPM
- total PBMC: 200 nTPM
- eosinophil: 106 nTPM
- plasmacytoid DC: 80 nTPM
Brain region
- white matter: 57 nTPM
- medulla oblongata: 34 nTPM
- spinal cord: 27 nTPM
- thalamus: 25 nTPM
- choroid plexus: 25 nTPM
- pons: 24 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CYBB.
Disease | AllUniProt
Conditions CYBB is implicated in, by any mechanism.
- Granulomatous disease, chronic, X-linked (CGDX) MIM:306400
- Immunodeficiency 34 (IMD34) MIM:300645
Disease | GeneticClinVar
209 pathogenic / likely-pathogenic of 906 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Granulomatous disease, chronic, X-linked
- Chronic granulomatous disease
- Granulomatous disease, chronic, X-linked, variant
- X-linked Mendelian susceptibility to mycobacterial diseases due to CYBB deficiency
- Thyroid cancer, nonmedullary, 1
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.19
- gnomAD pLI
- 1
- gnomAD missense Z
- 2.19
- DepMap mean gene effect
- 0.12
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cellular response to cadmium ion
- cellular response to ethanol
- cellular response to L-glutamine
- defense response
- hydrogen peroxide biosynthetic process
- hypoxia-inducible factor-1alpha signaling pathway
- inflammatory response
- innate immune response
- monoatomic ion transmembrane transport
- positive regulation of angiogenesis
- positive regulation of tumor necrosis factor production
- respiratory burst
- response to aldosterone
- response to angiotensin
- response to nutrient
- response to xenobiotic stimulus
- superoxide anion generation
- superoxide metabolic process
Molecular functions
- FAD binding
- flavin adenine dinucleotide binding
- heme binding
- metal ion binding
- NAD(P)H oxidase H2O2-forming activity
- NADPH binding
- protein heterodimerization activity
- superoxide-generating NAD(P)H oxidase activity
- superoxide-generating NADPH oxidase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Cytochrome b245, heavy chain
- FAD-binding 8
- Ferric reductase, NAD binding domain
- Ferric reductase transmembrane component-like domain
- FAD-binding domain, ferredoxin reductase-type
- Riboflavin synthase-like beta-barrel
- Ferredoxin-NADP reductase (FNR), nucleotide-binding domain
- Respiratory burst oxidase/Ferric reductase
- Ferric reductase like transmembrane component
- FAD-binding domain
- Ferric reductase NAD binding domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CYBB in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CYBB as an antibody target. Whether an autoantibody or antibody against CYBB could matter depends on whether native CYBB is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CYBB is annotated at the cell surface, where native CYBB is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CYBB as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...